CLEVELAND, May 27, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that Providence Portland
Medical Center in Portland, Oregon
has begun patient treatments with the MRIdian® MR-Guided Therapy
System, a cutting-edge radiation therapy system that combines the
latest innovations in precision radiation delivery and
ground-breaking MR-guidance.
The MRIdian system at Providence Portland Medical Center is part
of The Elsie Franz Finley Radiation Oncology Center and Providence
Cancer Institute. MRIdian utilizes on-table soft tissue imaging to
allow oncologists to visualize, adapt and target using
diagnostic-quality anatomical detail that is unavailable with
conventional image-guided radiation therapy (IGRT)
technologies.
Areas of particular interest to the Providence Portland Medical
Center are the treatment of non-metastatic pancreatic, liver, and
prostate cancer using MRIdian, given the system's real-time
MR-guidance and on-table adaptive capabilities.
"This technology allows us to track the movements and monitor
changes in shape of the target and surrounding organs so that we
can modify the radiation beams to fit the picture of the moment,
not yesterday's. It permits stronger, shorter, more effective
treatments to be delivered with potentially fewer complications,"
according to Dr. Steven Seung,
Medical Director for Radiation Oncology and Gamma Knife Center of
Oregon, and a physician at The
Oregon Clinic.
We're pleased to have Providence Portland Medical Center join
the growing list of hospitals bringing the benefits of MRIdian to
their patients," said Paul Ziegler,
Senior Vice President of Sales and Marketing at ViewRay. "As
hospitals explore ways to deliver effective cancer treatments while
also minimizing patient visits during these challenging times,
MRIdian's ability to deliver radiation therapy in fewer treatment
sessions becomes even more valuable."
Currently 37 MRIdian systems are installed at hospitals around
the world, where they are used to treat a wide variety of solid
tumors and are the focus of numerous ongoing research efforts.
MRIdian has been the subject of hundreds of peer-reviewed
publications, scientific meeting abstracts and presentations. More
than 9,000 patients have been treated with MRIdian. For a list of
treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy system.
MRIdian is built upon a proprietary high-definition MR imaging
system designed from the ground up to address the unique challenges
and clinical workflow for advanced radiation oncology. Unlike MR
systems used in diagnostic radiology, MRIdian's high-definition MR
was purpose built to address specific challenges, including beam
distortion, skin toxicity, and other concerns that potentially may
arise when high magnetic fields interact with radiation beams.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Private Securities Litigation Reform Act. Statements in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements include, among other
things, the rate of new orders, upgrades and installations,
ViewRay's financial guidance for the full year 2020 and ViewRay's
conference calls to discuss its first quarter 2020 and year to date
results. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to commercialize MRIdian Linac
System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2019 and its 2019 Quarterly Reports
on Form 10-Q, as updated periodically with the company's other
filings with the SEC. These forward-looking statements are made as
of the date of this press release, and ViewRay assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/providence-portland-medical-center-begins-patient-treatments-with-viewrays-mridian-linac-301065724.html
SOURCE ViewRay, Inc.